About Anocca
Anocca is a company based in Sodertalje (Sweden) founded in 2014. It operates as a HealthTech. Anocca has raised $129.86 million across 4 funding rounds from investors including Danske Bank, Swedbank and European Investment Bank. Anocca offers products and services including TCR-T Cell Therapy. Anocca operates in a competitive market with competitors including Sana Biotechnology, Janux Therapeutics, GigaGen, Kronos Bio and Carisma Therapeutics, among others.
- Headquarter Sodertalje, Sweden
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Anocca Ab (Publ)
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$129.86 M (USD)
in 4 rounds
-
Latest Funding Round
$46 M (USD), Series D
Aug 19, 2025
-
Investors
Danske Bank
& 7 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Anocca
Anocca offers a comprehensive portfolio of products and services, including TCR-T Cell Therapy.
TCR-T therapies are developed for untreatable cancer targets.
People of Anocca
Unlock access to complete
Unlock access to complete
Funding Insights of Anocca
Anocca has successfully raised a total of $129.86M across 4 strategic funding rounds. The most recent funding activity was a Series D round of $46 million completed in August 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Anocca
Anocca has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include Danske Bank, Swedbank and European Investment Bank.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Long-term value is created by Nidoco through active ownership.
|
Locked | Locked | Locked | |
|
Finance and advisory services for infrastructure projects are provided.
|
Locked | Locked | Locked |
Investor details for Anocca
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Anocca
Investment portfolio details for Anocca
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Anocca
Detailed financials for Anocca
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Anocca Comparisons
Peer comparison for Anocca
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Anocca
Anocca operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sana Biotechnology, Janux Therapeutics, GigaGen, Kronos Bio and Carisma Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Immunotherapeutics for cancer treatment are developed to target solid tumors.
|
|
| Locked | Locked | Locked |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Chimeric antigen receptor macrophages are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Developer of immunotherapies for the treatment of cancer and autoimmune diseases
|
Detailed competitors of Anocca
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Anocca
Complete news archive for Anocca
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Anocca
Anocca was founded in 2014 and raised its 1st funding round 7 years after it was founded.
Anocca is headquartered in Sodertalje, Sweden. It is registered at Sodertalje, Stockholm County, Sweden.
Anocca is a funded company, having raised a total of $129.86M across 4 funding rounds to date.
Anocca is engaged in creating precision T-cell immunotherapies for untreatable cancers. Novel approaches to T-cell biology are combined with cutting-edge biotechnologies and integrated software. The primary focus is on engineering TCR-T cell therapies targeting disease markers inside cancer cells. Systematic discovery platforms and modular biotechnologies are utilized to identify therapeutic targets and build effective solutions in the oncology sector.
Anocca's top competitors include Janux Therapeutics, Kronos Bio and Sana Biotechnology.
Anocca offers TCR-T Cell Therapy.
Anocca has 8 investors. Key investors include Danske Bank, Swedbank, European Investment Bank, AMF, and Mellby Gård.